Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis - Wikidata - awgldk - TriplyDB

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

http://www.wikidata.org/entity/Q29036090

about

Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy.The Prevalence of Anti-Aquaporin 4 Antibody in Patients with Idiopathic Inflammatory Demyelinating Diseases Presented to a Tertiary Hospital in Malaysia: Presentation and Prognosis.MOG antibody-related disorders: common features and uncommon presentations.B cells and their cytokine activities implications in human diseases.The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review.Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis.MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome.Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.Kallikrein 6 secreted by oligodendrocytes regulates the progression of experimental autoimmune encephalomyelitis.Pattern Recognition of the Multiple Sclerosis Syndrome.Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.'Leukodystrophy-like' phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease.Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody.Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.Clinical presentation and prognosis in MOG-antibody disease: a UK study.Etiologies of acute demyelinating optic neuritis: an observational study of 110 patients.Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.[Optical coherence tomography in neuromyelitis optica spectrum disorders].Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.Defining distinct features of anti-MOG antibody associated central nervous system demyelination.Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders

P2860

Q33645795-9228F342-F11C-4457-9265-C8C15BE28C07 Q33841113-8E7D4CE3-6113-43E7-976A-20DDA608A0B3 Q37374434-12C80192-DBA7-480B-99A8-717D3FF6FCFD Q37590294-85DC65EB-E403-497E-9434-0E86118FEA79 Q37620245-E8895FAE-30D3-4B84-A1C5-0D83DF6C8F36 Q38645211-E456CBC4-DC81-487D-9D3C-C8CE8FCB737C Q38665740-D65E4888-00CB-4F27-8A95-36B75167E505 Q38714054-12F9C697-F207-46D6-B0DA-D40C94AE88B7 Q38853499-755842A2-1AA6-4A70-B965-FD27373F474C Q39149611-FBC7D870-F311-4C82-9CD1-34ECD488CC95 Q41927942-BEF25129-B8FB-41C1-AF62-C99395E3460F Q42361527-8FC82EB8-F344-4269-846E-01DD39E39DF3 Q42627948-83413783-0877-40F3-A6E0-D3F8B135DCDD Q44875571-F5C7AD34-2CC2-4D98-B4B3-D6F756736E3A Q46894047-1516810D-2421-4A41-B7C0-1907126BA8D1 Q47096340-C652E349-C88F-4716-8819-AB56F9F9CD79 Q47163794-F304F455-36EC-40BC-BA88-671B7BC56498 Q47210450-2D601F55-41DE-47BD-AA2C-E8B361968C95 Q47284937-BC529AE1-BC26-428B-9DCB-AED7DC7935FD Q47396320-57521146-C2ED-4549-884F-C6F890ABDA12 Q47555447-9F4C6712-1B47-439C-B102-9DAA020D3FA9 Q47970245-A5322A05-ECD9-4ACB-B4A4-7A0CDB1E42F5 Q48182524-53BEF8C7-E383-40F4-942E-E00BC6D09643 Q48235947-91C4A9C2-1E38-4DE0-A4BC-86F25A05921F Q50101454-D0A48A3B-9D85-405C-8A74-68F59CE24FF1 Q51327401-5ECE2E94-BCB3-4D18-B19A-334B1CF82935 Q52603606-535C30E9-9E5D-4BA6-9422-8A41E9CD283B Q52668258-5AAA1573-31D8-4B07-9CA6-30D5D4A7D664 Q52803391-16691A9F-8920-42C3-BF6F-99F2AB4F78C6 Q55221002-55D91095-B8D2-4FC2-B1DC-AEDAE47CCFF1 Q58573155-A4295304-BD09-4B9C-8089-F9440DEB5712 Q58698171-9FEB617E-440A-4BC8-9EF4-5BA6519B1F99

P2860

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

http://www.wikidata.org/entity/Q29036090

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

@ast

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

@en

type

label

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

@ast

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

@en

prefLabel

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

@ast

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

@en

P1433

Q29036090-C1339BA4-52B0-4E9D-96F3-0AFA899F15FA

P1476

Q29036090-A5C291CE-70E5-478B-BF58-CC008F669B7C

P2093

Q29036090-140AE101-E148-48ED-9963-1A34BBCF4A25

Q29036090-4387E47E-F17B-460E-8767-0E8D5B365B72

Q29036090-5EA58C7A-BB2E-48D8-9D9A-17849741BCB5

Q29036090-656D635C-37E4-49BF-B4A2-0DC96DDBED50

Q29036090-7C9CBF92-1535-4577-921B-A7184BDCD9C4

Q29036090-810AFE51-64A8-45F5-A6BD-104C821885DD

Q29036090-8272A851-A1F0-47F6-9F18-9195F71FA163

Q29036090-99635C66-DA2A-43E0-B620-0CDA94172607

Q29036090-A4167DD7-B14D-4351-B986-5FC921491AD0

Q29036090-AD318ED1-8B85-44F1-9A7D-63416153F264

P2860

Q29036090-0F19CCFA-F114-47DB-9455-5092D22CFBBA

Q29036090-17FD885C-A4B1-4780-9CDC-FC2535857E4F

Q29036090-1A96FC1D-3F92-4AF3-B28F-1B64FDDEB4F9

Q29036090-1E75E96B-8BBE-401B-963D-58532B729E4B

Q29036090-24318E8F-02EA-4ADD-BB54-B01492B46E13

Q29036090-2BD30C7B-50ED-43C3-B830-D05DCEFD2930

Q29036090-2BD96753-41B3-491B-AAD1-D44D572A10D5

Q29036090-351CC59B-76C8-4C0F-A344-0BC2B94EBC3D

Q29036090-362AD0C3-88C8-436C-9D30-C12947820F9C

Q29036090-3F7DCEFC-A470-4A73-93C1-1B91559B6CA7

P304

Q29036090-63821D23-5CCA-4377-9CFA-F7BC14DC159C

P31

Q29036090-92398B92-1CF4-4D07-A303-D8B7B79D1C2A

P3181

Q29036090-C75A82EE-0A2A-499B-B980-B3D9B8AC5800

P356

Q29036090-A903554C-38D4-4B96-83BC-2E87607B5BA4

P433

Q29036090-2ADA2C02-C87A-48EE-AB66-EC5891599954

P478

Q29036090-4F82D269-04D5-4A9A-B7C6-17C7C554533B

P50

Q29036090-47BE0249-1F8B-43F0-B776-1A876A91717B

P577

Q29036090-1E751FE4-861A-4A93-B95D-6050DE5F6BB6

P698

Q29036090-610530B6-7AAF-4643-B1CC-BB43E93EFECE

P921

Q29036090-8D982506-BCE2-43BC-9AAA-1DF2B47D88D4

Q29036090-C75DC906-A900-4B47-93DB-FB5BF5BB7961

P932

Q29036090-FADCF19E-22D9-43F9-AD29-D957AF5D5968

P3181

P356

NXI.0000000000000257

P1433

Neurology(R) neuroimmunology & neuroinflammation

P1476

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

@en

P2093

Andrea Dick

http://www.w3.org/2001/XMLSchema#string

Astrid Blaschek

http://www.w3.org/2001/XMLSchema#string

Birgit Ertl-Wagner

http://www.w3.org/2001/XMLSchema#string

Edgar Meinl

http://www.w3.org/2001/XMLSchema#string

Elisabeth Schuh

http://www.w3.org/2001/XMLSchema#string

Franziska Sabrina Thaler

http://www.w3.org/2001/XMLSchema#string

Imke Metz

http://www.w3.org/2001/XMLSchema#string

Lisa Ann Gerdes

http://www.w3.org/2001/XMLSchema#string

Markus Krumbholz

http://www.w3.org/2001/XMLSchema#string

Melania Spadaro

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort

Histopathology and clinical course of MOG-antibody-associated encephalomyelitis

Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

The spectrum of MOG autoantibody-associated demyelinating diseases

The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

P304

e257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3331606

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/NXI.0000000000000257

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27458601

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4949775

http://www.w3.org/2001/XMLSchema#string